Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
More from our immunotherapy special report: [ Ссылка ]
![](https://i.ytimg.com/vi/Cq8LxsxZUVY/mqdefault.jpg)
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
More from our immunotherapy special report: [ Ссылка ]